These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

178 related items for PubMed ID: 22170566

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Plasma membrane localization signals in the light chain of botulinum neurotoxin.
    Fernández-Salas E, Steward LE, Ho H, Garay PE, Sun SW, Gilmore MA, Ordas JV, Wang J, Francis J, Aoki KR.
    Proc Natl Acad Sci U S A; 2004 Mar 02; 101(9):3208-13. PubMed ID: 14982988
    [Abstract] [Full Text] [Related]

  • 24. Identification of fibroblast growth factor receptor 3 (FGFR3) as a protein receptor for botulinum neurotoxin serotype A (BoNT/A).
    Jacky BP, Garay PE, Dupuy J, Nelson JB, Cai B, Molina Y, Wang J, Steward LE, Broide RS, Francis J, Aoki KR, Stevens RC, Fernández-Salas E.
    PLoS Pathog; 2013 Mar 02; 9(5):e1003369. PubMed ID: 23696738
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Association of botulinum neurotoxin serotype A light chain with plasma membrane-bound SNAP-25.
    Chen S, Barbieri JT.
    J Biol Chem; 2011 Apr 29; 286(17):15067-72. PubMed ID: 21378164
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Characterization of SNARE cleavage products generated by formulated botulinum neurotoxin type-a drug products.
    Hunt T, Rupp D, Shimizu G, Tam K, Weidler J, Xie J.
    Toxins (Basel); 2010 Aug 29; 2(8):2198-212. PubMed ID: 22069680
    [Abstract] [Full Text] [Related]

  • 31. Cleavage of SNAP25 and its shorter versions by the protease domain of serotype A botulinum neurotoxin.
    Mizanur RM, Stafford RG, Ahmed SA.
    PLoS One; 2014 Aug 29; 9(4):e95188. PubMed ID: 24769566
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Use of a recombinant fluorescent substrate with cleavage sites for all botulinum neurotoxins in high-throughput screening of natural product extracts for inhibitors of serotypes A, B, and E.
    Hines HB, Kim AD, Stafford RG, Badie SS, Brueggeman EE, Newman DJ, Schmidt JJ.
    Appl Environ Microbiol; 2008 Feb 29; 74(3):653-9. PubMed ID: 18083881
    [Abstract] [Full Text] [Related]

  • 35. Light chain separated from the rest of the type a botulinum neurotoxin molecule is the most catalytically active form.
    Gul N, Smith LA, Ahmed SA.
    PLoS One; 2010 Sep 22; 5(9):e12872. PubMed ID: 20877571
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Deubiquitinating enzyme VCIP135 dictates the duration of botulinum neurotoxin type A intoxication.
    Tsai YC, Kotiya A, Kiris E, Yang M, Bavari S, Tessarollo L, Oyler GA, Weissman AM.
    Proc Natl Acad Sci U S A; 2017 Jun 27; 114(26):E5158-E5166. PubMed ID: 28584101
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.